News Nestle bids to take control of Seres’ C diff drug Vowst Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upg
R&D Why gut bacteria is the next frontier in medicine Scientists search far and wide for treatments and cures for the diseases that cause great amounts of human suffering, from cancer to Parkinson's.
News Vedanta scores $106.5m to take microbiome drug into ph3 In the face of a challenging biotech financing environment, Vedanta Bio has ra
News FDA accepts review of SeresTx BLA for oral microbiome therap... The FDA has accepted for review Seres Therapeutics’ Biologics License Application (BLA) for SER-109, an investigational oral
Oncology On the forefront of healthcare change, turning innovative sc... Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face